| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Adult T cell leukemia (ATL) is a lymphoproliferative disorder caused by infection with HTLV-I. Although various chemotherapies have shown significant complete remission rates, most of the treated patients relapse. These data indicate the existence of leukemic stem cells (LSCs) and a specific niche that protects from chemotherapies. We identified that ATL-LSCs have reproduced the original tumor. Using homing assay, we found that more than 60% of first colonized cells in the spleen and BM were AT-LSCs and ATL-LSCs were also attached to the reticular cells in the trabecular bone. We also found the number of osteoclast was significantly increased at the trabecular region. To clarify the role of osteoclast, we treated osteoclast inhibitor Zoledronic acid. As a result, ATL cells were dramatically reduced in the BM and extend the mouse survival rate significantly in this treatment. These data suggest osteoclast have a potential therapeutic target in the mouse model of ATL.
|
